Table II.
Correlation of BRAF V600E mutation with clinicopathologic factors in 30 patients with papillary carcinoma.
| BRAF V600E mutation | ||||||
|---|---|---|---|---|---|---|
| Variables | No. of patients | + (n=25) | - (n=5) | P-value | OR | 95% CI |
| Age, years | ||||||
| <55 | 6 | 4 | 2 | 0.254 | 1.00 | |
| ≥55 | 24 | 21 | 3 | 0.29 | 0.04–2.30 | |
| Sex | ||||||
| Male | 3 | 2 | 1 | 0.434 | 1.00 | |
| Female | 27 | 23 | 4 | 0.35 | 0.02–4.80 | |
| Tumor size, cm | ||||||
| <2 | 14 | 11 | 3 | 0.642 | 1.00 | |
| ≥2 | 16 | 14 | 2 | 0.52 | 0.07–3.70 | |
| Stage | ||||||
| I, II | 21 | 18 | 3 | 0.622 | 1.00 | |
| III, IVB | 9 | 7 | 2 | 1.71 | 0.23–12.60 | |
| pT | ||||||
| 1a-3b | 19 | 18 | 1 | 0.047 | 1.00 | |
| 4a, 4b | 11 | 7 | 4 | 10.29 | 1.00–109.00 | |
| pN | ||||||
| 0, 1a | 21 | 20 | 1 | 0.019 | 1.00 | |
| 1b | 9 | 5 | 4 | 16.00 | 1.45–177.00 | |
| Extrathyroidal extension | ||||||
| − | 5 | 5 | 0 | 0.556 | 1.00 | |
| + | 25 | 20 | 5 | 1.25 | 1.02–1.52 | |
| Multifocality | ||||||
| − | 16 | 14 | 2 | 0.642 | 1.00 | |
| + | 14 | 11 | 3 | 1.91 | 0.27–13.50 | |
P-values were calculated with Fisher's exact test. OR, odds ratio; CI, confidence interval; pT, pathological T stage; pN, pathological N stage.